Trials / Conditions / Myelofibrosis Transformation in Essential Thrombocythemia
Myelofibrosis Transformation in Essential Thrombocythemia
5 registered clinical trials studyying Myelofibrosis Transformation in Essential Thrombocythemia — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People NCT07362225 | MPN Research Foundation | — |
| Active Not Recruiting | Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis NCT04517851 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essent NCT04054245 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Po NCT02421354 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myel NCT01787487 | M.D. Anderson Cancer Center | Phase 2 |